Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swissmedic, the Swiss Agency for Therapeutic Products, has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Subscribe to our email newsletter
In Switzerland, Jetrea will be launched by ThromboGenics’ partner Alcon, a division of Novartis.
Jetrea is the first pharmacological treatment for VMT and was approved by the European Commission (EC) in the European Union (EU) in March 2013.
Alcon, which received rights to commercialize Jetrea outside the US in March 2012, had launched the drug in the UK in April 2013.
The drug is currently available and reimbursed in the UK, Germany, Denmark, Finland, Norway, Sweden, Ireland, the Netherlands and Canada.
The company said that first patients have been treated with Jetrea in Belgium, France, Spain and Italy.
In January 2013, ThromboGenics had launched the drug in the US for the treatment of symptomatic vitreomacular adhesion (VMA).
Jetrea has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the US and Europe which involved 652 patients with vitreomacular adhesion.
In both the trials, the drug met the primary endpoint of resolution of VMA at day 28.